CDC

HIV/AIDS groups letter in support of MassHealth making injectable long-acting PrEP available without barriers

HIV/AIDS groups are concerned that MassHealth (Massachusetts Medicaid) has not yet added cabotegravir, a new long-acting injectable form of pre-exposure prophylaxis (PrEP) to prevent HIV, to its formulary. We urge MassHealth to make sure injectable long-acting cabotegravir as PrEP is available on formulary without any barriers to access, such as utilization management or prior authorization requirements.

read more

Testimony in support of increased funding for domestic HIV and hepatitis programs in the House FY 2023 Labor, HHS spending bill

On behalf of the HIV+Hepatitis Policy Institute, we respectfully submit this testimony in support of increased funding for domestic HIV and hepatitis programs in the FY 2023 Labor, HHS spending bill. Our nation is on a path to eliminating two infectious diseases, HIV and viral hepatitis, but we need increased funding to accelerate our efforts particularly in communities and populations disproportionately impacted. Increased investment in surveillance, education, prevention, and care and treatment will ensure we continue to address HIV and viral hepatitis, including taking a syndemic approach to achieve maximum impact. The programs and funding increases detailed below are pivotal to our nation’s ability to end both HIV and hepatitis.

read more

Testimony on FY 2023 appropriations for HIV and hepatitis programs

On behalf of the HIV+Hepatitis Policy Institute, we respectfully submit this testimony in support of increased funding for domestic HIV and hepatitis programs in the FY 2023 Labor, HHS spending bill. The HIV+Hepatitis Policy Institute is a leading HIV and hepatitis policy organization promoting quality and affordable healthcare for people living with or at risk of HIV, hepatitis, and other serious and chronic health conditions.

read more

CDC responds to HIV community request led by HIV+Hep to allow HIV prevention funds for PrEP ancillary services

We know that access to quality PrEP care is critical to HIV prevention efforts and we will continue to work with our partners to look for ways to expand PrEP services and commit to equitably expanding access to and uptake of PrEP. As part of Ending the HIV Epidemic in the U.S., state and local communities (in partnership with CDC and other federal agencies) are employing innovative strategies, such as telePrEP and same-day PrEP delivery, to increase access to and use of PrEP. These efforts focus on African American and Latino gay and bisexual men, African American women, and other populations disproportionately affected by HIV. We appreciate the input from you and your co-signatories and our partnership in HIV prevention.

read more

Comments in support of hepatitis B universal adult vaccination

HIV+Hep strongly supports a recommendation for universal hepatitis B vaccination for all adults. The hepatitis B vaccine is safe and effective, with over 1 billion doses administered worldwide and is estimated to have prevented over 310 million infections worldwide between 1990 and 2020. Despite highly effective vaccines, up to 2.4 million people in the United States may be living with chronic hepatitis B, and there are up to 80,000 new cases of hepatitis B each year. With the proper guidance and resources, each new infection is preventable.

read more

Pin It on Pinterest